INC Research, a, global phase I to IV CRO, has appointed Judith Ng-Cashin, M.D., as chief scientific officer. Dr. Ng-Cashin will lead the integration of the Company’s industry-recognized therapeutic and medical/scientific expertise for phase I to IV clinical trials. She will be responsible for scientific, medical and ethical governance matters, including collaboration with key medical and scientific stakeholders to strengthen INC’s position as a collaborative partner to clinical practice, sponsor and academic organizations.

“INC has long been recognized as the therapeutically-focused CRO,” said Michael Gibertini, Ph.D., president, Clinical Development. “The appointment of Dr. Judith Ng-Cashin further demonstrates our commitment to providing our customers with high-quality clinical development services grounded in practical medical science and industry-leading therapeutic expertise. With more than 20 years of experience in drug discovery and development, clinical research, bench science and clinical medicine, Dr. Ng-Cashin has distinguished herself in the development of novel therapies. Her proven track record will be invaluable as we work to further connect our medical and therapeutic teams at INC in support of our customers’ clinical development goals.”  

Dr. Ng-Cashin joins INC Research from another top-tier CRO where she served as vice president, Medical Strategy, Office of the CMSO with responsibility for oversight of medical ethics and governance across the global business and most recently as vice president, Advisory Services.  Her experience also includes nine years with GlaxoSmithKline in senior medical leadership roles. Dr. Ng-Cashin’s expertise is wide-ranging, spanning all stages of clinical research and including targeted research in melanoma, HIV and other infectious diseases.